Abstract
Despite many years of study, clinical trials of new drugs to prevent thrombosis have often been disappointing. Part of the problem lies in our incomplete understanding of the regulation of plasminogen activation and/or inhibition in vivo. We have previously shown that in vitro nitration of plasminogen in plasma by peroxynitrite resulted in decreased plasmin activity. We hypothesized that macrophages may be agents of plasminogen nitration and designed this study to prove this hypothesis. We first better characterized our previous observations using purified plasminogen instead of whole plasma, studied the time and concentration dependence of these reactions, and co-incubated plasminogen with macrophages, as well as with non-inflammatory cells as controls, to assess nitration and impaired activity. When plasminogen (10μmol/L) is incubated in the presence of SIN-1 (0.01–2mmol/L), plasmin activity (generated by streptokinase) is reduced in a time- and concentration-dependent fashion. We performed experiments incubating human plasminogen in the presence of murine RAW264.7 macrophages, allowing for free diffusion of reactive oxygen species, while preventing the action of proteases. In this way we show that incubation of plasminogen with macrophages also decreases plasmin activity, while increasing nitration of the molecule, an effect that is already apparent after 2h and reaches a plateau of 60% inhibition after 24h of incubation. This effect appears specific for macrophages, since 31EG4 murine mammary cells used in parallel and under the same conditions failed to produce any deleterious changes in plasminogen. Our data on quick functional inactivation of plasminogen by nitration, mediated by macrophages, adds a new pathophysiological dimension to our previous work showing plasminogen as a target for peroxynitrite damage. Nitrosative stress may be implicated in impaired fibrinolysis. New therapeutic approaches for nitrosative stress in atherosclerosis and diabetes should limit the formation of superoxides and peroxynitrite.
References
1. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129:307–21.10.1111/j.1365-2141.2005.05444.xSearch in Google Scholar PubMed
2. Heiden M, Seitz R, Egbring R. The role of inflammatory cells and their proteases in extravascular fibrinolysis. Semin Thromb Hemost 1996; 22:497–501.10.1055/s-2007-999050Search in Google Scholar PubMed
3. Longstaff C, Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Lett 2005; 579:3303–9.10.1016/j.febslet.2005.03.058Search in Google Scholar PubMed
4. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28:1357–64.10.1038/sj.ijo.0802778Search in Google Scholar PubMed
5. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993; 42:1–7.10.2337/diab.42.1.1Search in Google Scholar PubMed
6. Gugliucci A. Human plasminogen is highly susceptible to peroxynitrite inactivation. Clin Chem Lab Med 2003; 41:1064–8.10.1515/CCLM.2003.164Search in Google Scholar PubMed
7. Nowak P, Kolodziejczyk J, Wachowicz B. Peroxynitrite and fibrinolytic system: the effect of peroxynitrite on plasmin activity. Mol Cell Biochem 2004; 267:141–6.10.1023/B:MCBI.0000049370.23457.10Search in Google Scholar
8. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 1996; 271:C1424–37.10.1152/ajpcell.1996.271.5.C1424Search in Google Scholar PubMed
9. Botti H, Trostchansky A, Batthyany C, Rubbo H. Reactivity of peroxynitrite and nitric oxide with LDL. IUBMB Life 2005; 57:407–12.10.1080/15216540500137701Search in Google Scholar PubMed
10. Escobales N, Crespo MJ. Oxidative-nitrosative stress in hypertension. Curr Vasc Pharmacol 2005; 3:231–46.10.2174/1570161054368643Search in Google Scholar PubMed
11. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 2004; 101:4003–8.10.1073/pnas.0307446101Search in Google Scholar
12. Yamaguchi Y, Matsuno S, Kagota S, Haginaka J, Kunitomo M. Peroxynitrite-mediated oxidative modification of low-density lipoprotein by aqueous extracts of cigarette smoke and the preventive effect of fluvastatin. Atherosclerosis 2004; 172:259–65.10.1016/j.atherosclerosis.2003.09.030Search in Google Scholar
13. Hermo R, Mier C, Mazzotta M, Tsuji M, Kimura S, Gugliucci A. Circulating levels of nitrated apolipoprotein A-I are increased in type 2 diabetic patients. Clin Chem Lab Med 2005; 43:601–6.10.1515/CCLM.2005.104Search in Google Scholar
14. Schoenhagen P, Nissen SE. Coronary atherosclerosis in diabetic subjects: clinical significance, anatomic characteristics, and identification with in vivo imaging. Cardiol Clin 2004; 22:527–40.10.1016/j.ccl.2004.06.010Search in Google Scholar
15. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114:529–41.10.1172/JCI200421109Search in Google Scholar
16. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 2004; 279:42977–83.10.1074/jbc.M406762200Search in Google Scholar
17. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685–95.10.1056/NEJMra043430Search in Google Scholar
18. Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005; 3:63–8.10.2174/1570161052773861Search in Google Scholar
19. Loscalzo J. The macrophage and fibrinolysis. Semin Thromb Hemost 1996; 22:503–6.10.1055/s-2007-999051Search in Google Scholar
20. Laemmli UK, Amos LA, Klug A. Correlation between structural transformation and cleavage of the major head protein of T4 bacteriophage. Cell 1976; 7:191–203.10.1016/0092-8674(76)90018-0Search in Google Scholar
21. Soria J, Soria C, Samama M. [Plasminogen determination, using a chromogenic tripeptidic substrate]. Pathol Biol (Paris) 1976; 24:725–9.Search in Google Scholar
22. Sato J, Schorey J, Ploplis VA, Haalboom E, Krahule L, Castellino FJ. The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection. Am J Pathol 2003; 163:517–31.10.1016/S0002-9440(10)63680-2Search in Google Scholar
23. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001; 44:834–8.10.1007/s001250100529Search in Google Scholar PubMed
24. Busuttil SJ, Ploplis VA, Castellino FJ, Tang L, Eaton JW, Plow EF. A central role for plasminogen in the inflammatory response to biomaterials. J Thromb Haemost 2004; 2:1798–805.10.1111/j.1538-7836.2004.00916.xSearch in Google Scholar PubMed
25. Wang XL, Rainwater DL, Leone A, Mahaney MC. Effects of diabetes on plasma nitrotyrosine levels. Diabet Med 2004; 21:577–80.10.1111/j.1464-5491.2004.01211.xSearch in Google Scholar PubMed
26. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005; 93:647–54.10.1160/TH04-12-0842Search in Google Scholar PubMed
27. Miles LA, Hawley SB, Baik N, Andronicos NM, Castellino FJ, Parmer RJ. Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front Biosci 2005; 10:1754–62.Search in Google Scholar
28. Mundada LV, Prorok M, DeFord ME, Figuera M, Castellino FJ, Fay WP. Structure-function analysis of the streptokinase amino terminus (residues 1–59). J Biol Chem 2003; 278:24421–7.10.1074/jbc.M301825200Search in Google Scholar PubMed
29. Rebolledo OR, Actis Dato SM. Postprandial hyperglycemia and hyperlipidemia-generated glycoxidative stress: its contribution to the pathogenesis of diabetes complications. Eur Rev Med Pharmacol Sci 2005; 9:191–208.Search in Google Scholar
30. Bixby M, Spieler L, Menini T, Gugliucci A. Ilex paraguariensis extracts are potent inhibitors of nitrosative stress: a comparative study with green tea and wines using a protein nitration model and mammalian cell cytotoxicity. Life Sci 2005; 77:345–58.10.1016/j.lfs.2004.11.030Search in Google Scholar PubMed
31. Khan J, Brennand DM, Bradley N, Gao B, Bruckdorfer R, Jacobs M. 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method. Biochem J 1998; 330:795–801.10.1042/bj3300795Search in Google Scholar PubMed PubMed Central
32. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999; 103:1547–60.10.1172/JCI5549Search in Google Scholar PubMed PubMed Central
33. Shao B, Bergt C, Fu X, Green P, Voss JC, Oda MN, et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem 2005; 280:5983–93.10.1074/jbc.M411484200Search in Google Scholar PubMed
34. Zheng L, Settle M, Brubaker G, Schmitt D, Hazen SL, Smith JD, et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 2005; 280:38–47.10.1074/jbc.M407019200Search in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
